New hope for CML patients with Hard-to-Treat mutation?
NCT ID NCT06514534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing the drug asciminib in 20 adults with chronic myeloid leukemia who have a specific genetic change (T315I mutation) and cannot take the standard drug ponatinib. The goal is to see if asciminib can control the leukemia and improve outcomes. Participants take asciminib pills twice a day, and the study will measure how well the cancer responds after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
asciminib (Scemblix®)
What this could lead to
If successful, asciminib could offer a new treatment option for CML patients with the T315I mutation who have run out of other therapies.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGBordeaux, 33076, France
-
Novartis Investigative Site
RECRUITINGLille, 59037, France
-
Novartis Investigative Site
RECRUITINGLyon, 69373, France
-
Novartis Investigative Site
RECRUITINGNantes, 44093, France
-
Novartis Investigative Site
RECRUITINGParis, 75475, France
-
Novartis Investigative Site
RECRUITINGVandœuvre-lès-Nancy, 54511, France